NANOLOGIX ANNOUNCED EUROPEAN CLINICAL TRIAL OF ITS RAPID DETECTION KITS

Trial to study NanoLogix live-cell microorganism tests for the detection and identification of Group B Streptococcus in pregnant women

HUBBARD, OH--June 07, 2011--NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy. The 300 patient trial will study the speed and accuracy of NanoLogix technology compared to current methods in the detection and identification of Group B Streptococcus (GBS) in pregnant women. Initial BNF results on GBS from the University of Texas Health Science Center-Houston show detection and identification within two to six hours. This is eight to twenty-four times faster than conventional methods. The trial will be the second clinical trial conducted on the NanoLogix BNF technology for Group B Strep. Results from this clinical trial will accelerate the approval of the BNF kits for use in Europe, North Africa and the Middle East.
Conventional technology can take at least 48-72 hours to return results for Group B Strep. Often durning this waiting period it is recommended that physicians treat patients empirically with antibiotics if they fall into specified “at risk” categories for being colonized with GBS. This practice protects the mother from health risks and the unborn child from life threatening illnesses related to Group B Strep. However, it can also lead to the development of antibiotic resistance in GBS strains.
About 30 percent of reproductive age women carry GBS, which can cause life- threatening infections (such as sepsis, meningitis and pneumonia), in newborns if their mothers are not treated prior to delivery. In the U.S., delivery without treatment results in around 8,000 newborns being infected each year. The Centers for Disease Control guidelines for the prevention of neonatal GBS call for testing all pregnant women for GBS between 35 and 37 weeks. In 2009, just over 4 million women gave birth in the U.S. alone.
“We are excited to have our BioNanoFilter technology undergo a clinical trial in Europe,” said NanoLogix CEO Bret Barnhizer. “We expect this European clinical trial to pave the way for certification and validation of our rapid detection technologies there, as well as in North Africa and the Middle East. We thank Dr. Di Renzo and the other physicians and technicians who are involved in the trial.”

Success at 2011 American Society for Microbiology General Meeting

NanoLogix had a very successful exhibit at the American Society for Microbiology General Meeting in New Orleans last week. Interest was renewed with a Japanese firm and new interest was generated from various parties including the US Navy, US Army, US Department of Agriculture (USDA), and the Centers for Disease Control and Prevention (Atlanta).

NanoLogix Shipping Product For Testing

Based on the success of the ASM and other business building activities, the company is shipping BNP and BNF kits for testing and use to the USDA and a major food processing company, during the month of June. The kits are to be used for internal food processing screening purposes.

Update on University of Texas Health Science Center Trial

The first phase of the University of Texas Health Science Center clinical trial was accepted for publication by a major peer-reviewed journal. The name of the journal will be announced upon publication of the UTHSC paper. For more information, go to www.nanologix.com

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco- kinetics, and antibiotic sensitivity. For more information visit www.nanologix.com.

Media Contact:
Lisa Ann Pinkerton
650-288-1824
Lisaann@technicacommunications.com

Investor Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: carol@nanologix.com

Copyright 2011 NanoLogix, Inc All Rights Reserved

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

TAGS: NanoLogix, NNLX, biotechnology, BioNanoPore, BioNanoFilter, Quick Test Kit, science, technology, packaging, quality assurance, food safety, contamination, Group B Strep, GBS, Group B Streptococcus, University of Perugia, Italy, Europe, rapid test, rapid diagnostics, rapid detection, rapid identification, Petri dish, bacterial, pathogen, microbiology.